Literature DB >> 17566616

Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.

Gregory E D Mullen1, Joan A Aebig, Gelu Dobrescu, Kelly Rausch, Lynn Lambert, Carole A Long, Aaron P Miles, Allan Saul.   

Abstract

CpG oligodeoxynucleotides are potent immunostimulants. In this study, CPG 7909 was formulated with the recombinant Plasmodium falciparum protein AMA1-C1 adsorbed to Alhydrogel (aluminum hydroxide) and used to immunize mice. Mice receiving free CPG 7909 in a separate same site injection to the AMA1-C1/Alhydrogel had the same antibody responses as mice receiving AMA1-C1/Alhydrogel alone. For mice immunized with CPG 7909 bound to the AMA1-C1/Alhydrogel formulation, there was a bell shaped CPG 7909 dose-response curve with the highest antibody response co-incident with the concentration of CPG 7909 that saturated binding to the Alhydrogel. At a higher CPG 7909 dose where 74% was unbound, there was no enhancement of response over AMA1-C1/Alhydrogel alone. Our results suggest that the adjuvant effects of CpGs are optimal when adsorbed to Alhydrogel and highlight the need for careful characterization of the vaccine formulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17566616      PMCID: PMC1997297          DOI: 10.1016/j.vaccine.2007.05.007

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity.

Authors:  H Tighe; K Takabayashi; D Schwartz; R Marsden; L Beck; J Corbeil; D D Richman; J J Eiden; H L Spiegelberg; E Raz
Journal:  Eur J Immunol       Date:  2000-07       Impact factor: 5.532

2.  Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.

Authors:  C L Cooper; H L Davis; M L Morris; S M Efler; A M Krieg; Y Li; C Laframboise; M J Al Adhami; Y Khaliq; I Seguin; D W Cameron
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

3.  Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.

Authors:  Claire-Anne Siegrist; Maria Pihlgren; Chantal Tougne; Sue M Efler; Mary Lou Morris; Mohammed J AlAdhami; D William Cameron; Curtis L Cooper; Jenny Heathcote; Heather L Davis; Paul-Henri Lambert
Journal:  Vaccine       Date:  2004-12-16       Impact factor: 3.641

4.  Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.

Authors:  Aaron P Miles; Holly A McClellan; Kelly M Rausch; Daming Zhu; Michael D Whitmore; Sanjay Singh; Laura B Martin; Yimin Wu; Birgitte K Giersing; Anthony W Stowers; Carole A Long; Allan Saul
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

5.  Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Authors:  G Hartmann; R D Weeratna; Z K Ballas; P Payette; S Blackwell; I Suparto; W L Rasmussen; M Waldschmidt; D Sajuthi; R H Purcell; H L Davis; A M Krieg
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

6.  In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Authors:  Michael C Kennedy; Jin Wang; Yanling Zhang; Aaron P Miles; Farideh Chitsaz; Allan Saul; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.

Authors:  C L Cooper; H L Davis; M L Morris; S M Efler; M Al Adhami; A M Krieg; D W Cameron; J Heathcote
Journal:  J Clin Immunol       Date:  2004-11       Impact factor: 8.317

8.  CpG motifs in bacterial DNA trigger direct B-cell activation.

Authors:  A M Krieg; A K Yi; S Matson; T J Waldschmidt; G A Bishop; R Teasdale; G A Koretzky; D M Klinman
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

9.  Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.

Authors:  Sanjay Singh; Michael C Kennedy; Carole A Long; Allan J Saul; Louis H Miller; Anthony W Stowers
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 10.  Use of CpG oligodeoxynucleotides as immune adjuvants.

Authors:  Dennis M Klinman; Debra Currie; Ihsan Gursel; Daniela Verthelyi
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

View more
  11 in total

1.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Mimetics of hormetic agents: stress-resistance triggers.

Authors:  Joan Smith Sonneborn
Journal:  Dose Response       Date:  2010-01-06       Impact factor: 2.658

3.  TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity.

Authors:  Jun Du; Zhiyuan Wu; Shurong Ren; Yong Wei; Meihua Gao; Gwendalyn J Randolph; Chunfeng Qu
Journal:  Vaccine       Date:  2010-07-15       Impact factor: 3.641

4.  Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.

Authors:  Feng Qian; Kelly M Rausch; Olga Muratova; Hong Zhou; Guanhong Song; Ababacar Diouf; Lynn Lambert; David L Narum; Yimin Wu; Allan Saul; Louis H Miller; Carole A Long; Gregory E D Mullen
Journal:  Vaccine       Date:  2008-03-27       Impact factor: 3.641

5.  A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.

Authors:  Ruth D Ellis; Gregory E D Mullen; Mark Pierce; Laura B Martin; Kazutoyo Miura; Michael P Fay; Carole A Long; Donna Shaffer; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  Vaccine       Date:  2009-05-15       Impact factor: 3.641

6.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

7.  Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Authors:  Christopher B Fox; Mark T Orr; Neal Van Hoeven; Sarah C Parker; Traci J T Mikasa; Tony Phan; Elyse A Beebe; Ghislain I Nana; Sharvari W Joshi; Mark A Tomai; James Elvecrog; Timothy R Fouts; Steven G Reed
Journal:  J Control Release       Date:  2016-11-12       Impact factor: 9.776

8.  Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.

Authors:  Veena V Rao; C Steven Godin; Michael J Lacy; Jon R Inglefield; Sukjoon Park; Bruna Blauth; Joshua J Reece; Boris Ionin; Vladimir Savransky
Journal:  Int J Toxicol       Date:  2021-07-19       Impact factor: 2.032

9.  Mechanism of immunopotentiation and safety of aluminum adjuvants.

Authors:  Harm Hogenesch
Journal:  Front Immunol       Date:  2013-01-10       Impact factor: 7.561

10.  Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.

Authors:  Gregory E D Mullen; Ruth D Ellis; Kazutoyo Miura; Elissa Malkin; Caroline Nolan; Mhorag Hay; Michael P Fay; Allan Saul; Daming Zhu; Kelly Rausch; Samuel Moretz; Hong Zhou; Carole A Long; Louis H Miller; John Treanor
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.